Nitrogen In R Patents (Class 514/626)
-
Publication number: 20130197003Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: GALDERMA LABORATORIES, INC.Inventor: GALDERMA LABORATORIES, INC.
-
Patent number: 8497305Abstract: Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl, acetyl, haloacetyl, benzoyl, benzyloxy carbonyl (Cbz), t-butoxy carbonyl (Boc), or 9-fluorenyl methoxyl carbonyl (Fmoc). The present novel compounds have pharmaceutical activity and are prepared by condensation reaction of racemic, levo- or dextro-demethyl Sibutramine and racemic or D/L isoleucine under a mild condition. It is demonstrated that the present compounds have effect of losing weight to obese mode rats in different level and the effect is better than Sibutramine by the animal experiments. So the medicaments prepared by the present compounds or the medicaments prepared by the compositions of the present compounds and other pharmaceutical activity compounds may be used for treating obesity.Type: GrantFiled: March 24, 2009Date of Patent: July 30, 2013Assignee: YinGu Pharmaceutical Co., LtdInventors: Shuqiang Zhao, Shouming Wen, Hao Ding, Yashi Yan, Xiaoping Chen
-
Publication number: 20130184351Abstract: This invention is directed to a transdermal delivery patch comprising local anesthetic agent and optionally a permeation enhancement agent for reducing neuropathic pain.Type: ApplicationFiled: December 20, 2012Publication date: July 18, 2013Applicant: JAR LABORATORIESInventor: JAR LABORATORIES
-
Publication number: 20130178463Abstract: A buccal delivery system is disclosed suitable for delivery of a therapeutic agent to the oral cavity of a patient. The delivery system comprises a matrix for containing and releasing the therapeutic agent into the oral cavity and an alkyl N,N-disubstituted amino acetate in said matrix. A particularly preferred delivery system comprises a matrix containing an effective amount of therapeutic agent together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate salt.Type: ApplicationFiled: September 23, 2011Publication date: July 11, 2013Applicants: Rutgers, The State University of New Jersey, Nexmed Holdings, Inc.Inventors: Bassam B. Damaj, Richard Martin, Bozena Michniak-Kohn, Long-Sheng Hu
-
Publication number: 20130172387Abstract: Disclosed herein is a method for prolonging analgesic effect of a membrane permeable local anesthetic in a subject in need thereof. The method uses cinnamaldehyde as an adjuvant which, when administered prior to or simultaneously with the administration of a local anesthetic, prolongs the analgesic effect of the local anesthetic. Also disclosed herein is a method for providing analgesic effect in a subject in need thereof. The method uses cinnamaldehyde as an analgesic compound which, when administered alone to the subject in an analgesically effective amount, provides the analgesic effect.Type: ApplicationFiled: December 29, 2011Publication date: July 4, 2013Inventor: Yu-Chun HUNG
-
Publication number: 20130172422Abstract: Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents.Type: ApplicationFiled: February 25, 2013Publication date: July 4, 2013Applicant: ABSORPTION PHARMACEUTICALS, LLCInventor: Absorption Pharmaceuticals, LLC
-
Publication number: 20130150311Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.Type: ApplicationFiled: December 13, 2011Publication date: June 13, 2013Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
-
Publication number: 20130142781Abstract: Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.Type: ApplicationFiled: December 3, 2012Publication date: June 6, 2013Applicant: INVIVO THERAPEUTICS CORPORATIONInventor: InVivo Therapeutics Corporation
-
Patent number: 8449863Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.Type: GrantFiled: March 25, 2010Date of Patent: May 28, 2013Assignee: Lyotropic Therapeutics, Inc.Inventor: David Anderson
-
Publication number: 20130129824Abstract: A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.Type: ApplicationFiled: December 28, 2012Publication date: May 23, 2013Applicant: TARIS BIOMEDICAL, INC.Inventor: TARIS Biomedical, Inc.
-
Patent number: 8445536Abstract: A composition for increasing blood flow is provided, wherein side effects such as lowering of blood pressure are reduced and blood flow is effectively increased in the capillaries. A composition containing arginine in an amount from 25 mg/kg body weight to 150 mg/kg body weight is also provided. A food composition or a feeding stuff containing the composition is also provided. Method of using the above compositions to increase blood flow is also provided.Type: GrantFiled: March 30, 2006Date of Patent: May 21, 2013Assignee: Ajinomoto Co., Inc.Inventors: Fumio Ohta, Tomo Takagi, Hiroyuki Sato
-
Publication number: 20130116329Abstract: A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-? related activity level by more than comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition.Type: ApplicationFiled: May 13, 2011Publication date: May 9, 2013Applicant: ISIFER ABInventor: Greta Edelstam
-
Publication number: 20130116328Abstract: The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics.Type: ApplicationFiled: March 31, 2011Publication date: May 9, 2013Applicant: PHARMANEST ABInventors: Mark Sundberg, Arne Brodin, Nils Kållberg
-
Publication number: 20130109756Abstract: Dual drug paste compositions are disclosed containing a silicone organic elastomer gel, a hydrophobic drug, and a hydrophilic drug. The dual drug paste compositions are useful for the simultaneous delivery of a hydrophobic and hydrophilic drug to a substrate without the drawbacks of using traditional gels, solutions or emulsions.Type: ApplicationFiled: May 20, 2011Publication date: May 2, 2013Applicant: DOW CORNING CORPORATIONInventors: Robert Huber, Kathryn Messner, Linda Nartker, Victor Raul, Gerald Schalau
-
Publication number: 20130108573Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: Lumena Pharmaceuticals, Inc.Inventor: Lumena Pharmaceuticals, Inc.
-
Publication number: 20130102626Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Inventors: Peter Wipf, Marie Celine Frantz
-
Patent number: 8420112Abstract: A retrievable, sustained release, solid dosage form is provided for implanting into cranial bony canals and for prolonged release of an anesthetic, whereby treating neurovascular conditions, such as migraine. The dosage comprises an anesthetic contained in a polymeric carrier, and a retrieval member, the anesthetic being gradually released from the carrier.Type: GrantFiled: March 19, 2009Date of Patent: April 16, 2013Assignee: Paindure Ltd.Inventors: Alon Shalev, Itschak Lamnsdorf
-
Publication number: 20130089577Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders.Type: ApplicationFiled: March 11, 2011Publication date: April 11, 2013Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, JR.
-
Publication number: 20130079404Abstract: It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.Type: ApplicationFiled: November 19, 2012Publication date: March 28, 2013Applicant: Nuvo Research Inc.Inventor: Nuvo Research Inc.
-
Publication number: 20130079415Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.Type: ApplicationFiled: February 16, 2011Publication date: March 28, 2013Applicant: Jagotec AGInventors: Guy Vergnault, Pascal Grenier
-
Publication number: 20130078299Abstract: Crosslinked hydrogel-based transdermal pharmaceutical formulations. The hydrogel transdermal formulations. Transdermal patches are useful for administering a variety of drugs to patients. The transdermal patches here employ crosslinked-hydrogels generated through irradiation, thus eliminating any residual effects associated with chemical- or UV-based crosslinking procedures. The transdermal patches may be formed from a variety of high-molecular weight polymeric compounds and include substantial levels of water to improve skin tolerance by the patient. The transdermal patches may also include transcutol as a solvent for the drug, which has been found to increase the effectiveness of drug delivery. The present disclosure also provides for methods of loading a drug into a transdermal formulation after the crosslinking of the hydrogel, thus improving stability and bioavailability through avoiding exposure of the drug to the radiation used in the crosslinking procedure.Type: ApplicationFiled: April 11, 2012Publication date: March 28, 2013Applicant: Alliqua, Inc.Inventors: Matthew HARRITON, Gregory Robb, Ronald S. Harland
-
Publication number: 20130079371Abstract: The present invention relates to a gelling bioadhesive pharmaceutical composition comprising one or more local anaesthetics in base form and which is suitable for topical administration. The compositions have anisotropic organic phase behaviour that admits swelling at administration site with excess water.Type: ApplicationFiled: March 31, 2011Publication date: March 28, 2013Applicant: PHARMANEST ABInventors: Mark Sundberg, Arne Brodin, Jonas Gustafsson
-
Publication number: 20130079344Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.Type: ApplicationFiled: March 14, 2012Publication date: March 28, 2013Applicant: OMEROS CORPORATIONInventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Publication number: 20130071450Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.Type: ApplicationFiled: November 15, 2012Publication date: March 21, 2013Applicant: COVIDIEN LPInventor: Covidien LP
-
Publication number: 20130071445Abstract: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Applicant: Kalium, Inc.Inventors: Paul ZUPKAS, C. Lowell Parsons
-
Publication number: 20130059829Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.Type: ApplicationFiled: July 20, 2012Publication date: March 7, 2013Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Chen, Jurgen Dinges, Karla Drescher, Peer Jacobson, Hwan-soo Jae, Ravi Kurukulasuriya, James T. Link, David J. Madar, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Lynne E. Rueter, Qi Shuai, Bryan K. Sorensen, Jiahong Wang, Karsten M. Wicke, Martin Winn, Dariusz Wodka, Vince Yeh, Hong Yong
-
Publication number: 20130058880Abstract: Compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses are disclosed. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. The siloxane can have a hydrophilic group. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film. The compositions and kits, optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent. Such a film can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray.Type: ApplicationFiled: May 9, 2011Publication date: March 7, 2013Inventor: Shaosheng Dong
-
Publication number: 20130059910Abstract: A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.Type: ApplicationFiled: September 6, 2012Publication date: March 7, 2013Applicants: Bar-Ilan University, Ramot at Tel-Aviv University Ltd.Inventors: Abraham NUDELMAN, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Publication number: 20130059914Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.Type: ApplicationFiled: April 8, 2011Publication date: March 7, 2013Applicant: SIGNATURE THERAPEUTICS, INC.Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 8389768Abstract: Provided herein are novel cationic lipids, compositions comprising the cationic lipids, and methods of using the cationic lipids. In some claims, the cationic lipids have cytotoxic activity and can be used alone or in combination with a cytotoxic bioactive compound to kill a cell. In some of these claims, the cationic lipid enhances the cytotoxic activity of the cytotoxic bioactive compound. Methods for treating a subject afflicted with a disease or unwanted condition are provided, wherein the method comprises administering a delivery system comprising a novel cationic lipid to the subject. The invention further provides methods for making delivery systems comprising the novel cationic lipids of the invention.Type: GrantFiled: May 1, 2009Date of Patent: March 5, 2013Assignee: The University of North Carolina at Chapel HillInventors: Leaf Huang, Yunching Chen, Joyeeta Sen, Surendar Reddy Bathula, Sumio Chono, Shyh-Dar Li, Michael Hackett
-
Publication number: 20130053418Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
-
Publication number: 20130053447Abstract: Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents.Type: ApplicationFiled: October 5, 2012Publication date: February 28, 2013Applicant: Absorption Pharmaceuticals, LLCInventor: Absorption Pharmaceuticals, LLC
-
Publication number: 20130045979Abstract: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: August 14, 2012Publication date: February 21, 2013Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Publication number: 20130046025Abstract: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises at least one essential oil as an abirritant to minimize skin irritation caused by tolterodine. The composition relieves skin irritation caused by tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.Type: ApplicationFiled: February 17, 2011Publication date: February 21, 2013Applicant: SK Chemicals Co., Ltd.Inventors: Yong Youn Hwang, Won-Jae Choi, Jae-Sun Kim, Yeo-Jin Park, Joon-Gyo Oh, Bong-Yong Lee, Hae-In Rhee, Jong-Seob Im
-
Publication number: 20130046275Abstract: A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.Type: ApplicationFiled: July 19, 2012Publication date: February 21, 2013Applicant: THERACOAT LTD.Inventors: Asher HOLZER, Dorit DANIEL, Michael MULLERAD, Jaime DE LA ZERDA, Uri SHPOLANSKY, Nadav MALCHI, Yosh DOLLBERG, Dor TAL, Yossi YAVIN, Marina KONORTY
-
Publication number: 20130041039Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.Type: ApplicationFiled: October 16, 2012Publication date: February 14, 2013Applicant: ALLERGAN INDUSTRIE, SASInventor: Allergan Industrie, SAS
-
Publication number: 20130041038Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.Type: ApplicationFiled: October 16, 2012Publication date: February 14, 2013Applicant: ALLERGAN INDUSTRIE, SASInventor: Allergan Industrie, SAS
-
Publication number: 20130035351Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.Type: ApplicationFiled: August 3, 2011Publication date: February 7, 2013Applicant: SOUTHWEST RESEARCH INSTITUTEInventors: Stanton F. MCHARDY, Richard M. CORBETT, Donald M. MAXWELL, Michael W. TIDWELL, Bismarck CAMPOS, Christopher J. BEMBEN
-
Publication number: 20130035296Abstract: The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted ? amino acid, each of the substituting groups in the ? amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.Type: ApplicationFiled: November 2, 2010Publication date: February 7, 2013Applicant: LYTIX BIOPHARMA ASInventors: Morten Strom, Terkel Hansen, Martina Havelkova, Veronika Torfoss
-
Publication number: 20130022553Abstract: The present invention relates to novel polyamino polyketide antibiotics, methods of their production as well as methods of using these antibiotics, for example, for inhibition or removal of biofilm formation or for treating bacterial infection with these antibiotics.Type: ApplicationFiled: November 9, 2009Publication date: January 24, 2013Applicant: Agency for Science, Technology and ResearchInventors: Jien Wu, Haibao Zhang, Lianhui Zhang
-
Publication number: 20130023520Abstract: An eye drop solution includes an anaesthetic and at least one medicament. The anaesthetic is preferably provided in a range of from about 0.001% to about 1.0%. The eye drop solution may further include either a lubricant or a preservative, or both of these.Type: ApplicationFiled: July 24, 2011Publication date: January 24, 2013Inventor: Amir Sahba Jalali
-
Publication number: 20130011342Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.Type: ApplicationFiled: October 1, 2010Publication date: January 10, 2013Applicant: FOAMIX LTD.Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan, Nukzi Papiashvile
-
Publication number: 20130012502Abstract: Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.Type: ApplicationFiled: December 7, 2010Publication date: January 10, 2013Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Manuel Rosa-Calatrava, Jean-Jacques Diaz, Julien Textoris, Laurence Josset
-
Publication number: 20120322783Abstract: Disclosed herein are solutions and kits for tumescent antibiotic delivery. Embodiments of the solution comprise an antibiotic component, an anesthetic component and a vasoconstrictor component. In addition, a method of use is disclosed comprising subcutaneous delivery of the solution. The disclosed solution, kit and method of subcutaneous delivery can be used for a variety of surgical procedures including liposuction, mastectomy and others. The tumescent antibiotic solution can be administered to a patient in situations where establishing IV access is difficult, impossible, or undesirable. A variety of delivery methods appropriate for surgical settings, as well as for use by first responders are likewise disclosed.Type: ApplicationFiled: November 30, 2010Publication date: December 20, 2012Inventor: Jeffrey Alan Klein
-
Publication number: 20120322840Abstract: A transdermally absorbable preparation in which a basic anti-inflammatory analgesic is formulated is provided to be an external adhesive patch, which has excellent drug releasing without damaging the physical properties of a plaster. The preparation can achieve high releasing of the basic anti-inflammatory analgesic without losing the releasing of the local anesthetic. Specifically provided is a transdermally absorbable adhesive patch, which contains both the basic anti-inflammatory analgesic and the local anesthetic as the absorption promoter for the basic anti-inflammatory analgesic. The basic anti-inflammatory analgesic has the acid dissociation constant (pKa) of 7 or more. The content of the basic anti-inflammatory analgesic is from 0.1% to 10% by weight to the total weight of the drug-containing plaster, and the content of the absorption promoter is from 0.01% to 20% by weight to the total weight of the drug-containing plaster in the transdermally absorbable adhesive patch.Type: ApplicationFiled: December 14, 2010Publication date: December 20, 2012Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Akiko Katayama, Katsuyuki Inoo
-
Publication number: 20120309623Abstract: Provided in various embodiments are surface-modified hydrogels and hydrogel microparticles, methods for their preparation, and uses thereof for delivery of personal care and healthcare active ingredients, and agricultural active ingredients. In some embodiments, such hydrogels and hydrogel microparticles comprise surface coatings that are resistant to solvent washing and can act as barriers for the migration of water and/or water-compatible alcohols and actives soluble therein.Type: ApplicationFiled: February 17, 2011Publication date: December 6, 2012Inventors: Dongchan Ahn, James Thompson
-
Patent number: 8324190Abstract: Methods of treating cancer using compounds according to Formula (I) are disclosed herein, wherein X, X1, X2, Ra, R1, R2, R3, R4, R5, R6, R7, g, M, y, a, b, d, e, V, W, Z and Q are as defined herein.Type: GrantFiled: July 14, 2009Date of Patent: December 4, 2012Assignees: Temple University—Of The Commonwealth System of Higher Education, Onconova Therapeutics, Inc.Inventors: E. Premkumar Reddy, M. V. Ramana Reddy, Stanley C. Bell
-
Publication number: 20120301402Abstract: A method for assessing if a subject has or is at risk of developing cardiac arrhythmia is described. The method includes determining the activity of Rap1A protein in a bodily sample of the subject and comparing the activity of Rap1A protein from the bodily sample of the subject to at least one Rap1A control. A decreased level of Rap1A activity in the bodily sample of the subject as compared to the at least one Rap1A control indicates that the subject is at risk of developing or has cardiac arrhythmia. Methods for evaluating the efficacy of treatment of a subject having decreased Rap1A activity with an antiarrhythmic agent are also described.Type: ApplicationFiled: April 27, 2012Publication date: November 29, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Maqsood Ahmed Chotani, John Anthony Bauer, Mandar Shankar Joshi, Selvi Chrysolyte Jeyaraj
-
Publication number: 20120301517Abstract: The present invention is drawn to adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can have a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least two non-volatile solvents. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: August 3, 2012Publication date: November 29, 2012Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Patent number: 8318813Abstract: The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: GrantFiled: January 24, 2008Date of Patent: November 27, 2012Assignee: LCS Group, LLCInventor: Louis Sanfilippo